Full Text View
Tabular View
No Study Results Posted
Related Studies
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
This study has been completed.
First Received: April 20, 2004   Last Updated: August 20, 2008   History of Changes
Sponsor: Sanofi-Aventis
Information provided by: Sanofi-Aventis
ClinicalTrials.gov Identifier: NCT00081796
  Purpose

The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.


Condition Intervention Phase
Breast Cancer
Metastases
Drug: larotaxel (RPR109881, XRP9881)
Drug: capecitabine
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy

Resource links provided by NLM:


Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:
  • Time to tumor progression.

Secondary Outcome Measures:
  • Overall survival.

Enrollment: 438
Study Start Date: April 2004
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Detailed Description:

All patients in this trial will receive either the investigational drug or capecitabine, a chemotherapy drug that is already approved to treat your disease. These drugs prevent tumor cells from dividing, so they may stop growing or die. The investigational drug in this clinical trial is a chemotherapy drug given through the vein once every three weeks. Patients who receive capecitabine will receive this drug by mouth for 14 days, every 21 days.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria

In order to be eligible for this trial you must:

  • Have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery.
  • Have received previous treatment with anthracyclines (e.g., adriamycin, Doxorubicin) and taxanes (e.g., paclitaxel, docetaxel, Taxol®, Taxotere®) for your breast cancer and your doctor has determined that these treatment are no longer of benefit to you.
  • Be at least 18 years of age.
  • Not be taking other treatments for your cancer at the time you enter this trial.
  • Not be pregnant.

Additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (e.g., lab tests, CT scans).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00081796

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States, 35216
United States, Arizona
Tucson, Arizona, United States, 85704
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Fountain Valley, California, United States, 92708
Gilroy, California, United States, 95020
San Diego, California, United States, 92123
Pamona, California, United States, 91767
San Francisco, California, United States, 94115
Burbank, California, United States, 91505
Monterey Park, California, United States, 91754
Porterville, California, United States, 93257
Los Angeles, California, United States, 90095
Oxnard, California, United States, 93030
Pomona, California, United States, 91767
Fresno, California, United States, 93720
Bakersfield, California, United States, 93309
Long Beach, California, United States, 90806
Santa Barbara, California, United States, 93105
Concord, California, United States, 94520
Fullerton, California, United States, 92835
Redondo Beach, California, United States, 90272
Vista, California, United States, 92081
Northridge, California, United States, 91328
Soquel, California, United States, 95073
United States, Connecticut
New London, Connecticut, United States, 06320
United States, Delaware
Newark, Delaware, United States, 19718
United States, Florida
Gainsville, Florida, United States, 32605
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32209
Lake Worth, Florida, United States, 33461
West Palm Beach, Florida, United States, 33401
Orlando, Florida, United States, 32804
Ft Lauderdale, Florida, United States, 33316
United States, Georgia
Lawrenceville, Georgia, United States, 30045
Macon, Georgia, United States, 31201
Marietta, Georgia, United States, 30060
Roswell, Georgia, United States, 30076
United States, Illinois
Centralia, Illinois, United States, 62801
Skokie, Illinois, United States, 66077
Chicago, Illinois, United States, 60640
Peoria, Illinois, United States, 61615
United States, Indiana
Fort Wayne, Indiana, United States, 46815
New Albany, Indiana, United States, 47150
United States, Kentucky
Lexington, Kentucky, United States, 40503
Hazard, Kentucky, United States, 41701
Danville, Kentucky, United States, 40422
United States, Louisiana
Shreveport, Louisiana, United States, 71101
Lafayette, Louisiana, United States, 70503
United States, Maryland
Annapolis, Maryland, United States, 21401
Baltimore, Maryland, United States, 21201
United States, Michigan
Southfield, Michigan, United States, 48076
St. Joseph, Michigan, United States, 49085
United States, Missouri
St. Louis, Missouri, United States, 63141
St. Louis, Missouri, United States, 63110
United States, Montana
Billings, Montana, United States, 59101
United States, New Jersey
Hackensack, New Jersey, United States, 07601
United States, New York
Utica, New York, United States, 13502
Nyack, New York, United States, 10960
United States, North Carolina
Charlotte, North Carolina, United States, 28203
Greenville, North Carolina, United States, 27834
Wilmington, North Carolina, United States, 28401
Winston-Salem, North Carolina, United States, 27103
Charlotte, North Carolina, United States, 28204
Raleigh, North Carolina, United States, 27609
Chapel Hill, North Carolina, United States, 27599
United States, North Dakota
Bismarck, North Dakota, United States, 58501
United States, Ohio
Cincinatti, Ohio, United States, 45267
Worthington, Ohio, United States, 43085
Cleveland, Ohio, United States, 44109
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Dunmore, Pennsylvania, United States, 18512
Hershey, Pennsylvania, United States, 17033
Philadelphia, Pennsylvania, United States, 19106
Philadelphia, Pennsylvania, United States, 19146
Philadelphia, Pennsylvania, United States, 19115
Kingston, Pennsylvania, United States, 18704
Pittsburgh, Pennsylvania, United States, 15213
Kttaning, Pennsylvania, United States, 16201
United States, South Carolina
Charleston, South Carolina, United States, 29425
Charleston, South Carolina, United States, 29403
Greenville, South Carolina, United States, 29615
United States, Tennessee
Nashville, Tennessee, United States, 37205
United States, Texas
Richardson, Texas, United States, 75082
Fort Worth, Texas, United States, 76104
Dallas, Texas, United States, 75390
United States, Virginia
Arlington, Virginia, United States, 22205
Abingdon, Virginia, United States, 24211
United States, Washington
Kirkland, Washington, United States, 98034
Spokane, Washington, United States, 99202
United States, West Virginia
Huntington, West Virginia, United States, 25701
Argentina
Santa Fe, Argentina
Buenos Aires, Argentina
Capital Federal, Argentina
Australia
Melbourne, Australia
St. Leonards, Australia
Sydney, Australia
Perth, Australia
Austria
Vienna, Austria
Bludesch, Austria
Brazil
Sao Paolo, Brazil
Brazil, San Paulo
Sorocaba, San Paulo, Brazil
Canada
Quebec, Canada
Montreal, Canada
Ottawa, Canada
Ontario, Canada
Canada, Newfoundland and Labrador
St. John's, Newfoundland and Labrador, Canada
Canada, Quebec
Levis, Quebec, Canada
Chile
Las Condes
Santiago, Chile
Santiago, Chile
Colombia
Medellin, Colombia
Bogota, Colombia
Cali Valle, Colombia
Czech Republic
Nora Ves Pod Plesi, Czech Republic
Ostrava, Czech Republic
Hradec Kralove, Czech Republic
Finland
oulu, Finland
Kemi, Finland
France
Besancon, France
Paris, France
Saint Herblain, France
Saint Cloud, France
Montpellier, France
Marseille, France
Lyon, France
Nice, France
Germany
Aschaffenburg, Germany
Berlin, Germany
Frankfurt, Germany
Halle, Germany
Oldenberg, Germany
Kiel, Germany
Heidelberg, Germany
Munich, Germany
Munchen Bayern, Germany
Hungary
Budapest, Hungary
Szeged, Hungary
Israel
Haifa, Israel
Tel HaShomer, Israel
Tel Aviv, Israel
Ashkelon, Israel
Beer-Sheva, Israel
Italy
Novara, Italy
Largo Agostino Gemelli, Italy
Pavia, Italy
Napoli, Italy
Modena, Italy
Bologna, Italy
Sassari, Italy
Cuneo, Italy
Livorno, Italy
Palermo, Italy
Korea, Republic of
Gyeonggi-Do, Korea, Republic of
Seoul, Korea, Republic of
Mexico
Mexico DF Distrio Federal, Mexico
Tuluea Estand de Mexico, Mexico
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Poland
Warsaw, Poland
Kracow, Poland
Portugal
Coimbra, Portugal
Lisboa, Portugal
Beja, Portugal
Porto, Portugal
Romania
Cluj Napoca, Romania
Craiova, Romania
Bucharest, Romania
Slovenia
Maribor, Slovenia
South Africa
Pretoria, South Africa
Durban, South Africa
Johannesburg, South Africa
Capetown, South Africa
Parktown, South Africa
Spain
Jaen, Spain
Madrid, Spain
Navarra, Spain
Valencia, Spain
Alicante, Spain
Taiwan
Taipai, Taiwan
Taoyuang, Taiwan
United Kingdom
Ipswich, United Kingdom
Nottingham, United Kingdom
Manchester, United Kingdom
Surrey, United Kingdom
London, United Kingdom
Bristol, United Kingdom
Birmingham, United Kingdom
United Kingdom, Carduff
Cardiff, Carduff, United Kingdom
Sponsors and Collaborators
Sanofi-Aventis
Investigators
Study Director: ICD CSD Sanofi-Aventis
  More Information

No publications provided

Responsible Party: sanofi-aventis ( ICD Study Director )
Study ID Numbers: EFC6089, XRP9881B-3001
Study First Received: April 20, 2004
Last Updated: August 20, 2008
ClinicalTrials.gov Identifier: NCT00081796     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi-Aventis:
Metastatic Breast Cancer

Additional relevant MeSH terms:
Antimetabolites
Capecitabine
Antimetabolites, Antineoplastic
Skin Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Breast Neoplasms
Pharmacologic Actions
Neoplasms
Neoplastic Processes
Neoplasms by Site
Pathologic Processes
Therapeutic Uses
Neoplasm Metastasis
Breast Diseases

ClinicalTrials.gov processed this record on November 22, 2009